X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VIP152 (enitociclib) is a highly selective CDK9 inhibitor that prevents activation of RNA polymerase II, resulting in reduction of known oncogenes MYC and MCL1. It is currently in Phase 1/2 trials combination with venetoclax and prednisone for the treatment of Lymphoma.
Lead Product(s): Enitociclib,Venetoclax,Prednisone
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2024
Details:
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Findings demonstrate that VIP152 monotherapy inhibits tumor growth in an ovarian cancer xenograft model in mice. VIP152, the PTEFb/CDK9 inhibitor, used for treatment in gynecologic cancer cell lines and in patients with gynecologic malignancies.
Lead Product(s): Enitociclib,Pembrolizumab
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
VIP152, a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 inhibitor demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Orphan Drug Designation is based on ongoing Phase 1b expansion of VIP152, PTEFb/CDK9 inhibitor in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
The proceeds from the financing will support the clinical evaluation of VIP152, the Company’s potent and selective inhibitor of CDK9, in additional indications and combination regimens, as well as to advance its bioconjugation platform.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 16, 2021
Details:
Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.
Lead Product(s): Enitociclib
Therapeutic Area: Oncology Product Name: VIP152
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
